Navigation Links
Shield Therapeutics Signs Agreement With AOP Orphan for ST10-021
Date:11/1/2010

Shield Therapeutics Signs Agreement With AOP Orphan for ST10-021 -- WOLLERAU, Switzerland, November 1, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Contracts Click to view news release full screen  

Shield Therapeutics Signs Agreement With AOP Orphan for ST10-021

 

WOLLERAU, Switzerland, November 1, 2010 /PRNewswire/ --

- AOP Orphan to Make Strategic EUR3m Investment in Shield Holdings

Shield Holdings AG (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage hospital pharmaceuticals, today announces that it has signed a strategic commercialisation agreement for its lead asset, ST10-021, an iron therapy product which has commenced Phase III clinical development, with AOP Orphan Pharmaceuticals AG ("AOP"). AOP is a pharmaceutical company based in Vienna specialising in the development and marketing of medicines for rare and complex diseases.

Under the terms of the agreement, Shield, whose products address areas of high unmet medical need, will receive an upfront payment of EUR1.25m and further milestone-based payments of up to EUR1.75m. AOP will receive commercialisation rights to ST10-021 in Central Eastern Europe and the Middle-East, together with an equity stake in a subsidiary of Shield.

ST10-021, a novel stable complex of ferric iron in an oral formulation, is being developed as a daily prescription pharmaceutical iron therapy product with an initial indication for the treatment of iron deficiency anaemia ("IDA") associated with inflammatory bowel disease ("IBD"). IDA is a significant complication of IBD, affecting approximately 73% of patients with ulcerative colitis or Crohn's disease globally1,2. ST10-021 was acquired by Shield in Q1 2010 and has global patent protection through 2026.

Shield recently initiated a pivotal Phase III programme for ST10-021 as a treatment for IDA as a side-effect of both ulcerative colitis and Crohn's disease. Two parallel clinical trials will commence patient enrolment in 2011. The international, 12 week, multi-centre trials will include approximately 120 patients each and the primary endpoint of the studies will be measurement of haemoglobin improvement via a simple blood test. Tests conducted to date in nearly 400 humans suggest that ST10-021 may be safe and well tolerated, with the potential to provide a new therapy option that could overcome the clear limitations of current treatments.

Currently available oral treatments for IDA demonstrate limited effectiveness due to negative side-effect profiles and low levels of compliance. Intravenous therapies also have limitations as they are expensive, have the potential to cause hypersensitivity reactions and are inconvenient due to the requirement for hospital-based administration. Rapid absorption of ST10-021 in the upper gastro-intestinal tract may enable lower dosing and may mitigate the risk of unwanted gastro-intestinal side effects commonly observed with commercially available oral iron replacement therapies. In addition, it appears that the efficacy of ST10-021 is not dependent on an acidic gastric pH, so it may be able to be co-prescribed with commonly used gastric-acid reducers.

Shield Therapeutics was founded in 2008 and is led by Carl Sterritt (Chief Executive Officer) and Dr Christian Schweiger (Chief Medical Officer). Shield's management team has over 30 years experience in the successful development and commercialisation of pharmaceuticals, most recently including Thelin(R), Tracleer(R) and Remodulin(R). The team previously successfully established and led the European operations of Encysive Pharmaceuticals, before it was acquired by Pfizer Inc. in 2008.

The investment by AOP follows the completion of Shield's first external funding round in May 2010 in which the Company raised EUR1m.

Commenting on today's announcement, Carl Sterritt, Chief Executive Officer of Shield Holdings, said: "This investment by AOP provides further significant independent validation of ST10-021 and its development programme. It also has the added benefit of allowing Shield to leverage AOP's leading track record in the commercialisation of drugs to treat complex disease areas. We look forward to the initiation of patient recruitment into the Phase III programme in 2011 and are working closely with Regulators to best address the clear unmet medical need in the treatment of iron deficiency anaemia in IBD patients."

Commenting on today's announcement, Dr Rudi Widmann, Chief Executive Officer of AOP, said: "The cooperation between AOP and Shield will allow both companies to add significant value to their business strategy. AOP has a unique record of developing and distributing products for rare and complex diseases, thus Shield will benefit from AOP's access to treatment centres and its long term expertise in commercialising drugs for rare and complex diseases in Central Europe and the Middle East."

References

1. Gasche C, Anaemia in Inflammatory Bowel Disease, Uni Med Science 2008;

2. Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohn's disease. Aliment Pharmacol Ther 2006; 24:1507-152

About Shield

Shield, founded in 2008, is an independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need. Shield is currently preparing to undertake a global pivotal Phase III study of its lead asset, ST10-021, for the treatment of iron deficiency anaemia associated with inflammatory bowel disease. The Company is headquartered in Wollerau, Switzerland. For further information, please visit http://www.shieldtherapeutics.com.

About AOP

AOP is a pharmaceutical company specialising in the development and marketing of medicines for rare and complex diseases in Haematology/Oncology, Cardiovascular Disease, Metabolic Disorders and Neurology. The company is based in Vienna and is represented in all Central European countries and the Middle East. AOP also commercialises its products in South East Asia, South Africa and South America with a series of distribution partners. The Company is headquartered in Vienna, Austria. For further information, please visit http://www.aoporphan.at.

For more information about Shield, please contact: M:Communications Mary-Jane Elliott / Emma Thompson Tel +44(0)20-7920-2345 E-mail: shield@mcomgroup.com
'/>"/>

SOURCE Shield Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CareFusion and Blue Cross and Blue Shield of Illinois Create Illinois Hospital Quality Initiative to Help Eliminate Health Care-Associated Infections
2. Shield Healthcare Announces 10th Annual Caregiver Story Contest
3. Empire BlueCross BlueShield Expands Lab Networks -- Creating Broader Choice, Robust Competition and Lower Costs for Consumers
4. Regence BlueCross BlueShield Wins Peoples Voice Award for Online Consumer Campaign in the 14th Annual Webby Awards
5. MAQUET Cardiovascular Introduces New VASOSHIELD Pressure Controlling Syringe to Help Preserve Graft Integrity for Coronary Artery Bypass Surgery Patients
6. MiMedx Group Announces CE Mark for the HydroFix(TM) Spine Shield
7. Blue Cross and Blue Shield of Illinois Offers Consumer Tips for Safe Disposal of Prescription Drugs
8. CareFusion Signs Exclusive Partnership Agreement With Minimally Invasive Devices to Distribute FloShield Laparoscopic Technology
9. MiMedx Group Announces Launch of its Paradis Vaso Shield(TM) Device
10. Blue Shield of California Awards $29.6 Million in Pay-for-Performance Programs in 2009
11. vProtect(TM) Luminal Shield Stabilizes Vulnerable Plaque
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... CAMBRIDGE, Mass. , June 24, 2016 /PRNewswire/ ... the Spaulding Rehabilitation Network,s Dean Center for ... of Physical Medicine and Rehabilitation, MIT Hacking Medicine, ... Center for Innovation, today announced the five finalists ... Hackathon for Lyme disease.  More than 100 scientists, ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop ... The fitness app plans to fix the two major problems leading the fitness industry today:, ... all type program , They don’t eliminate all the reasons people quit their ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
Breaking Medicine News(10 mins):